SIGN UP

Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)

January 9, 2023 10:19 AM ESTUpdated 10:38 AM

AstraZeneca bets up to $1.8B on CinCor and its ex-Roche drug for hypertension

Nicole DeFeudis

Editor

CinCor Pharma’s hypertension drug may have failed a Phase II study, but that doesn’t scare AstraZeneca.

The pharma giant is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

view job offer post your job now

TRENDING NOW

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

sponsored

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence